Sublingual timolol--an alternative to topical medication in glaucoma?

Area of Science:

• Ophthalmology
• Pharmacology

Background:

• Elevated intraocular pressure (IOP) is a primary risk factor for glaucoma.
• Topical eye drops are the standard treatment, but administration can be challenging for certain patient groups.
• Alternative administration routes for IOP-lowering medications are needed.

Purpose of the Study:

• To evaluate the efficacy of sublingual timolol maleate in reducing elevated intraocular pressure.
• To compare sublingual administration with traditional topical instillation of timolol drops.
• To assess the potential of sublingual timolol for patients unable to self-administer eye drops.

Main Methods:

• A placebo-controlled, randomized, double-masked, crossover study was conducted.
• Twelve patients with ocular hypertension were included.
• Timolol maleate 0.5% drops or saline placebo were administered either topically to one eye or sublingually, with IOP, pulse, and blood pressure measured before and after.

Main Results:

• Sublingual timolol significantly reduced IOP in both the treated eye (mean reduction 7.55 mm Hg) and the fellow eye (mean reduction 7.7 mm Hg) after 2 hours.
• Topical timolol reduced IOP by 8.5 mm Hg in the treated eye and 1.66 mm Hg in the fellow eye.
• Both administration routes caused similar reductions in pulse rate, with no significant changes in blood pressure.

Conclusions:

• Sublingual timolol demonstrates significant IOP-lowering effects, nearly matching topical application efficacy at 2 hours.
• This route offers a practical alternative for glaucoma patients facing challenges with eye drop instillation.
• Further research may support sublingual timolol as a valuable option in glaucoma management.